Irinotecan, Cetuximab, And Bevacizumab (Cbi) Versus Irinotecan, Cetuximab, And Placebo (Ci) In Irinotecan-Refractory Metastatic Colorectal Cancer (Mcrc): Results From An Accru Network Randomized Phase Ii Trial

Marla Lipsyc-Sharf,Fang-Shu Ou,Matthew B. Yurgelun,Douglas Adam Rubinson,Deborah Schrag,Shaker R. Dakhil,Philip J. Stella,Douglas Jay Weckstein,Donald B. Wender,Meredith Gail Faggen,Tyler Zemla,Erica N. Heying,Samantha R Schuetz,Stephanie Noble,Jeffrey A. Meyerhardt,Tanios S. Bekaii-Saab,Charles S. Fuchs,Kimmie Ng

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 1|浏览82

暂无评分

摘要

102Background: Combination irinotecan and cetuximab is approved for irinotecan-refractory mCRC; it is unknown if the addition of bevacizumab would improve outcomes. We studied the efficacy and safe...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要